- Home
- CELC vs XPER Comparison
CELC vs XPER Comparison
Compare CELC & XPER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- XPER
- Stock Information
- Founded
- CELC 2011
- XPER 1990
- Country
- CELC United States
- XPER United States
- Employees
- CELC N/A
- XPER N/A
- Industry
- CELC Medical Specialities
- XPER Semiconductors
- Sector
- CELC Health Care
- XPER Technology
- Exchange
- CELC Nasdaq
- XPER Nasdaq
- Market Cap
- CELC 440.0M
- XPER 370.5M
- IPO Year
- CELC 2017
- XPER 2003
- Fundamental
- Price
- CELC $13.77
- XPER $7.54
- Analyst Decision
- CELC Strong Buy
- XPER Strong Buy
- Analyst Count
- CELC 6
- XPER 3
- Target Price
- CELC $30.67
- XPER $19.00
- AVG Volume (30 Days)
- CELC 245.9K
- XPER 228.4K
- Earning Date
- CELC 08-13-2025
- XPER 08-06-2025
- Dividend Yield
- CELC N/A
- XPER N/A
- EPS Growth
- CELC N/A
- XPER N/A
- EPS
- CELC N/A
- XPER N/A
- Revenue
- CELC N/A
- XPER $488,877,000.00
- Revenue This Year
- CELC N/A
- XPER $0.50
- Revenue Next Year
- CELC N/A
- XPER $8.71
- P/E Ratio
- CELC N/A
- XPER N/A
- Revenue Growth
- CELC N/A
- XPER N/A
- 52 Week Low
- CELC $7.58
- XPER $6.29
- 52 Week High
- CELC $19.77
- XPER $11.08
- Technical
- Relative Strength Index (RSI)
- CELC 59.12
- XPER 41.49
- Support Level
- CELC $13.47
- XPER $7.56
- Resistance Level
- CELC $14.57
- XPER $7.78
- Average True Range (ATR)
- CELC 0.65
- XPER 0.19
- MACD
- CELC -0.04
- XPER -0.03
- Stochastic Oscillator
- CELC 36.65
- XPER 17.05
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About XPER Xperi Inc.
Xperi Inc is a consumer and entertainment technology company. Its offering comprises a portfolio of software and services. The company creates extraordinary experiences at home and on the go for millions of consumers around the world, enabling audiences to connect with content in a more intelligent, immersive, and personal way. Its business is divided into four categories based on the products delivered and customers served: Pay-TV, Consumer Electronics, Connected Car, and Platform Solutions. It generates the majority of its revenue from the Consumer Electronics segment. Its also have sales in Japan, Europe and Middle East, China, South Korea, Latin America, and Others.